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CRMAGE: CRISPR Optimized MAGE 
Recombineering
Carlotta Ronda, Lasse Ebdrup Pedersen, Morten O. A. Sommer & Alex Toftgaard Nielsen
A bottleneck in metabolic engineering and systems biology approaches is the lack of efficient 
genome engineering technologies. Here, we combine CRISPR/Cas9 and λ Red recombineering based 
MAGE technology (CRMAGE) to create a highly efficient and fast method for genome engineering 
of Escherichia coli. Using CRMAGE, the recombineering efficiency was between 96.5% and 99.7% 
for gene recoding of three genomic targets, compared to between 0.68% and 5.4% using traditional 
recombineering. For modulation of protein synthesis (small insertion/RBS substitution) the efficiency 
was increased from 6% to 70%. CRMAGE can be multiplexed and enables introduction of at least two 
mutations in a single round of recombineering with similar efficiencies. PAM-independent loci were 
targeted using degenerate codons, thereby making it possible to modify any site in the genome. 
CRMAGE is based on two plasmids that are assembled by a USER-cloning approach enabling quick 
and cost efficient gRNA replacement. CRMAGE furthermore utilizes CRISPR/Cas9 for efficient plasmid 
curing, thereby enabling multiple engineering rounds per day. To facilitate the design process, 
a web-based tool was developed to predict both the λ Red oligos and the gRNAs. The CRMAGE 
platform enables highly efficient and fast genome editing and may open up promising prospective for 
automation of genome-scale engineering.
E. coli is one of the most widely used model organisms for metabolic engineering for production of a wide range 
of biochemicals1. The use of systems biology, synthetic biology and evolutionary engineering has enabled an 
extensive portfolio of genetic tools and protocols for efficient, fast and cheap manipulation in order to make E. 
coli suitable for industrial applications. Homologous recombination (RecET)2, group II intron retrohoming3–5 
and phage-derived recombinases (λ Red)6–8 have been applied to introduce modifications in the genome such 
as single point mutations or Knock-In/Out of genes. However in order to select for the recombinant clones, 
these methods rely on antibiotic markers, which have to be removed in order to introduce further modifications. 
Recycling of the selective marker can be achieved by using Cre-Lox recombinase5 or FLP flippase4 but both these 
enzymes leave scars in the genome. This limits the application for sequential allelic exchange since the scars will 
increase the risk of internal chromosomal rearrangements. In order to overcome the problem of selecting the 
recombinant strains and recycling of antibiotic markers, different methods of scarless counter-selection have been 
developed, including a SacB-based method9 and the use of the meganucleases such as Sce-I10,11. Despite the high 
efficiency of the counter-selection, the repeated engineering process becomes laborious and time consuming with 
multiple steps involved for the introduction of just a single modification. Additionally, the methods do not enable 
multiplexing since only few selective markers are available for combinatorial use.
The λ Red single/double-stranded DNA (ssDNA/dsDNA)-based mediated engineering is currently the only 
method that allows multiplexing in one step by direct electroporation of single stranded oligos or PCR products. 
For this reason it has been extensively used as editing tool and it has been employed for Multiplex Automated 
Genome Engineering (MAGE)12–14, a method that facilitates genome-scale engineering and barcoded genome 
profiling. It has recently been improved by co-operative oligonucleotide co-selection by leveraging selectable 
markers within 500 kb of multiple targets15. Moreover it has been demonstrated that it is possible to increase 
the number of recombinants by using mismatch repair mutants such as mutS16 and by using phosphorothioate 
linkages to protect the lagging-targeting strand in order to increase the half-life of the Oligos or PCR products 
and thus the probability of their incorporation during the replication17. The efficiency of short ssDNA/dsDNA 
oligonucleotide-mediated recombineering (including MAGE) is highest for short genome modifications, where 
around 6 to 20% can be achieved after single or multiple cycles respectively13,18, while larger modifications occur 
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with significantly lower frequency (< 1%)13,17. Therefore, PCR screening is always required18 making it challeng-
ing to identify the desired mutations that do not result in a clear phenotypic change.
CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats and its associated protein, Cas9) sys-
tem has recently proven to be a powerful tool for genome engineering in different organism, both Eukaryotes and 
Prokaryotes such as E. coli19–21 Actinomycetal spp22. Streptomyces spp.23,24, lactic acid bacteria25, S.cerevisiae26–31, 
higher plants32,33 Bombyx mori34, Drosophila35, Zebrafish36, human cell lines37,38 and CHO39–41 cells. The type 
II CRISPR-Cas system from Streptococcus pyogenes consists of the CRISPR- associated (Cas) protein, Cas9, a 
trans-activating CRISPR RNA (tracrRNA), and a programmable CRISPR targeting RNA (crRNA) that can be 
fused together to the tracrRNA in a synthetic sgRNA. Cas9 is a programmable nuclease that mediates blunt 
double-stranded break (DSB) at almost any target DNA locus were a PAM motif (protospacer-adjacent motif) is 
present at 3′ end42,43. In the case of S. pyogenes nuclease, the sgRNA scaffold can be programmed for a specific site 
by including 20 bp of the target locus at the 5′ position of the double guanine PAM motif (NGG) (20N-NGG). It 
is also possible to reprogram Cas9 by using tracrRNA and a synthetic array containing 30 bp of the target (5′ of 
NGG) embedded between two repeat regions that will be subsequently be processed in the mature crRNA42. In 
both cases the PAM motif is not included in the target sequence used for the sgRNA or crRNA array. CRISPR/
Cas9 can be used to create a selective pressure during the recombineering procedure. The nuclease activity targets 
the loci that have not incorporated the desired mutation, where it induces double strand breaks (DSB) that have a 
significant fitness cost and may even result in cell death. In E. coli, the CRISPR-Cas9 system has been recently cou-
pled to λ Red oligos recombineering in order to improve its efficiency19–21. Recently, Jiang et al.19 were able to reach 
high efficiency of recombineering using dsDNA oligos by expressing in succession the two systems. Pyne et al. 
have also recently demonstrated that the CRISPR/Cas9 system combined with λ Red is a promising strategy to 
facilitate scar-less large chromosomal gene replacement20 and multiple knock-outs and knock-ins of both small 
and large fragments21. However both of these methods rely mainly on dsDNA oligos, which always require all 
the λ Red proteins (exo, β and γ ) and it is not suitable for a high throughput genome scale approach based on 
chip-based synthetized oligos44,45. Additionally, the system reported by Jiang et al.19 system did not shown very 
high efficiencies when dsDNA was co-transformed with gRNA expressing plasmid. Li et al.46, have also demon-
strated the efficacy of using λ Red and CRISPR in metabolic engineering of E. coli for integrating the β -carotene 
synthetic pathway into the genome, and used the same method to optimize its production by modifying the 
methylerythriol-phosphate (MEP) pathway and the central metabolic pathways. So far, none of the established 
methods are compatible with automation, which could further increase engineering throughput.
Here, we aimed at generating a simple and highly effective tool, CRMAGE, which enables fast genome edit-
ing compatible with automation protocols. CRMAGE exploits intrinsic negative selection against the wild type 
of CRISPR/Cas9 in order to increase the MAGE performance for small genome modifications such as codon 
substitution or translation control elements. The system is based on two curable plasmids that encode optimized 
versions of both systems λ Red recombineering and CRISPR/Cas9. Since both MAGE and gRNA oligos are criti-
cal for the protocol, we additionally created a web based tool for automating and optimizing the oligo design. We 
furthermore demonstrated that degenerate codon usage can be used to expand the range of CRISPR targets, thus 
creating a powerful tool to modify any site in the genome by introducing different types of modifications such as 
standard knock-Out/In, point mutations and modulation of protein translation in a single step.
Results
Construction of the CRMAGE system. In order to increase the overall MAGE performance, CRMAGE 
technology exploits the ability of Cas9 to create DSB and thus kill cells that have not had the PAM sequence 
removed by the recombineering reaction. This method has been conceived to compact and optimize at 
the same time λ Red recombineering and CRISPR/Cas9 in one system ready to be applied for automation 
(Fig. 1). Therefore CRMAGE consist of just two plasmids, which are completely curable (Fig. 1). One plasmid 
(pMA7CR_2.0) expresses the λ Red β -protein and the CRISPR/Cas9 protein, which are inducible by L-arabinose 
and anhydrotetracyline (aTetracycline) respectively. The second vector is a recycling plasmid (pMAZ-SK) that 
contains an aTetracyline inducible sgRNA used for the negative selection, as well as a “self-destruction” gRNA 
cassette that targets the vectors own backbone in order to enable plasmid recycling and sequential recombineer-
ing steps (Fig. 1). The self-killing system consists on a tracrRNA that combines with two crRNAs, arranged in a 
natural CRISPR array (30 bp repeat − 30 bp target − 30 bp repeat − 30 bp target etc.), to target the pCOLA plasmid 
origin (Ori) and the kanamycin antibiotic marker upon induction with L-rhamnose and aTetracycline. The λ Red 
has been coupled to a transient mutS phenotype as detailed below, in order to optimize the recombineering step 
by having a transient deficient repair system. We have also attempted to increase the efficiency of the negative 
selection of CRISPR/Cas9 by coupling it with a transient recA- phenotype in order to promote cell death due to 
the inability to repair DSB as described below.
CRISPR/Cas9 Killing efficiency and estimation of fitness advantage for protocol optimiza-
tion. In order to investigate the efficacy of the CRISPR/Cas9 negative selection and to estimate the selection 
time required for the CRMAGE protocol we first determined the CRISPR/Cas9 killing rate and the chance of 
recombinants take-over using a gRNA targeting the metabolic gene encoding the galactokinase (galK). The galK 
gene was used as a target because loss of function of this gene is easy to screen for using MacConkey plates, where 
colonies capable of utilizing for example galactose will turn purple. The CRMAGE system (pMA7CR_2.0 and 
pMAZ-SK::galK2) was transformed into both the WT MG1655 strain and into an MG1655 strain harboring the 
galK mutation that confers CRISPR immunity. Using traditional recombineering, we constructed a galK mutant 
carrying a stop codon in position 38 (TAC > TAG), which causes truncation and loss of function of the galac-
tokinase (Table 1 and Fig. S1). By inducing the CRMAGE system targeting the wild type galK sequence in both 
backgrounds, the survival of each strain was followed over time. The two strains were inoculated with the same 
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amount of cells in two different flasks. Cells were grown exponentially to OD 0.4–0.5, after which the CRMAGE 
system was induced. Cells were plated before induction and each hour after induction and the killing rate was 
determined as the ratio of WT cells over the galk* mutant. Interestingly an almost complete killing of all WT cells 
was achieved only two hours after induction and almost no viable cells were detected after three hours (Fig. 2). 
Only few cells survived, potentially because the CRISPR system may be susceptible to escapers. Indeed only a sin-
gle point mutation in the PAM motif or in the seed region (8 nucleotides upstream the PAM) can create resistance 
and thereby eliminating the killing/selection activity. Additionally, a competition experiment with the two strains 
mixed was also performed and resulted in identical data.
RecA and mutS transient mutants contribution in CRMAGE optimization. In order to increase the 
efficiency of CRMAGE, we aimed at improving the efficiency of both the λ Red recombineering and the CRISPR/
Cas9 killing. Costantino et al. has proven that defects in the mismatch repair system can enhance the efficiency 
of recombineering more than 100-fold16. We therefore created a transient mutS- phenotype by overexpressing the 
Dam methyltransferase, since this has been documented to result in a mutator (mutS−) phenotype47–49. The Dam 
gene was expressed in an L-arabinose inducible synthetic operon together with the β -protein in order to obtain 
a transient mutator strain that can be induced only during the recombineering stage, thereby minimizing the 
creation of unwanted mutations. To optimize the negative selection of the CRISPR/Cas9 system, both Cas9 and 
recX were expressed in a synthetic operon under control of the pLTet promoter. It has previously been shown that 
overexpression of RecX inhibits RecA activity50,51, one of the major components of the DNA repair system. Since 
RecA mutants are not capable of repairing DSBs (Double Strand Break), we wished to investigate if overexpression 
Figure 1. Schematic cartoon of CRMAGE system. CRMAGE consist of two plasmids, pMA7CR_2.0 expresses 
λ /RED β -protein and CRISPR/Cas9 protein that are inducible by L-Arabinose and aTetracyline respectively. 
The β -proteins are co-expressed with dam, which gives a mutS mutator phenotype, and cas9 is expressed in a 
operon with recX, which blocks the repair of double strand breaks. The second plasmid (pMAZ-SK) contains 
an aTetracyline inducible sgRNA used for selection against the wild type sequence, as well as a self-eliminating 
circuit that targets its own backbone to enable plasmid recycling and sequential recombineering. Upon 
L-rhamnose induction (and aTetracycline for cas9 induction), a tracrRNA that combines with two crRNAs, 
arranged in a natural CRISPR in order to target the origin (Ori) and the antibiotic marker (Kanamycin).
Locus  
Genome
Sequence 
MAGE Oligo gRNA target sequence 
GFP_RBS 
Change 
//--TGGAGGACTTT--// //--TGTTCCTCTTT--// CTCCTTTGCTCATCTAGTAT 
Galk2.2_STO
P_synonymo
us codon 
//--ACCGACTACA --// //--ACAGACTAGA--// AACGAAACCGTCGTTGTAGT  
XylA_STOP //-- ATTCCGTCAC --// //-- ATTCTAGCAC --// GTTCGTCGGGATTGTAGTGA 
LacZ_STOP //--TATGACCATG--// //-- TATGTAGATG--// GGCCAGTGAATCCGTAATCA 
Table 1.  Oligos used for the CRMAGE experiments. Target sites are marked with red. Synonymous 
mutations are in blue.
www.nature.com/scientificreports/
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of the inhibitor (RecX) would enhance the CRMAGE negative selection. After one CRMAGE cycle using a galK 
MAGE oligo we observed that recX overexpression most likely has a smaller positive impact on CRMAGE effi-
ciency (p-value < 0.1) (Fig. 3), and we therefore decided to keep overexpression of recX in the CRMAGE system.
Use of CRMAGE to engineer PAM-dependent and independent genomic targets. After estimat-
ing the optimal killing window for CRMAGE, we wanted to test if the system could be used to target loci in the 
genome that are not directly linked to a PAM sequence. As proof of concept we decided to create a galK knockout 
by changing one of the initial codons of the gene, which is not directly linked to a PAM site, into a stop codon 
(TAC > TAG) (Table 1). To do this, we identified a PAM site in the closest proximity (within the 70 bp coverage 
of the MAGE oligo) and we introduced a secondary silent mutation that disrupts the nearby PAM sequence while 
coding for the same amino acid (ACC > ACA) (Table 1). After a single round of CRMAGE, we found that about 
98% (Fig. 4a) of the population had incorporated the desired mutation in galK. Using traditional MAGE only 5% 
of the population had the specific mutation incorporated (Fig. 4a), which is consistent with previous studies18. All 
mutations were confirmed by sequencing. This makes it theoretically possible to utilize the CRMAGE system to 
target any site in the genome with a very high efficiency thus further expanding the ability to investigate codon 
usage and re-coding of the essential genes, as it has been previously attempted using MAGE alone52. In order to 
investigate the robustness of the CRMAGE system, we tested two additional metabolic targets, xylA and lacZ. 
Using CRMAGE, a stop codon was introduced in both genes (Table 1 and Fig. S1), and the efficiency was assessed 
by plating on MacConkey plates. After a single round of CRMAGE, an efficiency of 99.7% and 96.5% was reached 
for xylA and lacZ respectively (Fig. 4a). Using traditional recombineering, only 0.6% efficiency for xylA and 3.6% 
for lacZ could be achieved, thus demonstrating the strength of CRMAGE.
Use of CRMAGE for small insertions and modulation of protein synthesis. The high efficiency 
of the CRMAGE system for achieving single point mutations prompted us to test if CRMAGE would enable 
larger genome modifications, which typically result in very low frequencies when relying on MAGE alone13,17. 
Figure 2. Wild type killing efficiency. The graph represents the killing of a wild type strain compared to a galK 
mutant over time. For each time point the cells were plated and the ratio between WT/galk* was calculated.
Figure 3. Contribution of RecX in CRMAGE efficiency. The graph shows the effect of recX expression on the 
CRISPR/Cas9 killing activity after λ Red recombineering. In pMA7CR_2.0 (represented by the dark grey bar on 
the right) cas9 was expressed in a synthetic operon together with recX. In pMA7CR2, cas9 was expressed alone 
(represented by light grey bar on the left). The presence of recX positively contributes to the negative selection 
(dark grey bar on the right) with p-value < 0.1 according to a T-test analysis.
www.nature.com/scientificreports/
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Since it is often desirable to modulate expression level of certain proteins, we tested if CRMAGE could be used 
to modify regulatory elements such as RBS sequences. A strain harboring a genome integrated GFP with a weak 
RBS was used. We then attempted to introduce an RBS variant (TCCTCC > AGGAAG) (Table 1 and Fig. S1) pre-
dicted to have significantly higher expression levels, thus resulting in higher fluorescence levels (GFP+). Using the 
CRMAGE system, an efficiency of 62% was achieved (Fig. 4b), while only 6% of the population had introduced 
the RBS modification when relying on MAGE alone (Fig. 4b). All insertions were confirmed by sequencing. This 
demonstrates that it is feasible to generate libraries of different regulatory elements with high efficiency using 
CRMAGE.
Use of CRMAGE for multiplexing. Given the high efficiency of introducing both single point mutations 
as well as a larger RBS modification, we decided to test if introduction of multiple mutations could be achieved in 
a single round of CRMAGE. In a wild type background, we therefore co-selected for the introduction of both the 
replacement of the RBS sequence in front of GFP and the introduction of a stop-codon in galK. The two different 
MAGE oligos were co-transformed together with two different gRNAs for CRISPR/Cas9 negative selection. The 
final population was plated on both MacConkey and LB plates and the efficiency was determined for each indi-
vidual mutation (Fig. 4c). In randomly picked colonies, 98% were found to carry the galK* mutation and 70% 
carried the RBS modification (Fig. 4c). Subsequently, recombinant clones for each mutation (GFP+ and galk*) 
were tested to determine if they also carried the second mutation. All the tested colonies (40 out of 40) showing 
Figure 4. Efficiency of CRMAGE. Panel (A,B) show the efficiency of CRMAGE for gene recoding using 
pMA7CR_2.0 compared to the pMA7 control using only λ Red. (A) The efficiency of CRMAGE for introducing 
codon substitution stop codons in xylA and lacZ. Additionally, a stop codon was introduced in galk* linked to a 
secondary silent codon substitution used by CRMAGE as counter selection. (B) The efficiency of substituting a 
weak RBS in front of GFP with a strong one (TCCTCC > AGGAAG) while disrupting the PAM sequence used 
for negative selection. Panel (C–D) shows the efficiency of multiplex CRMAGE. (C) The efficiency of a single 
round of CRMAGE for simultaneously introducing the two mutations mentioned above (the RBS exchange 
on the left and stop codon substitution on the right). (D) CRMAGE multiplexing efficiency (pMA7CR_2.0) of 
the two mutations compared to the control (pMA7) using only λ Red. The data result from the analysis of 15 
to 40 positive clones per each mutation that were re-streaked and tested if they were carrying also the second 
modification.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:19452 | DOI: 10.1038/srep19452
strong GFP fluorescence after CRMAGE also resulted in white colonies when plated on MacConkey plates, thus 
proving that they also incorporated the galK* mutation. Similarly, all the colonies tested (15 out of 15) carrying 
the galK* mutation also showed strong GFP expression, thus surprisingly resulting in a 100% efficiency of simul-
taneously introducing the double mutations (Fig. 4d). Using MAGE alone, only 5–6% of the colonies carried the 
galK* mutation, and of these only 10% carried showed strong GFP fluorescence (Fig. 4d). All alterations were 
confirmed by sequencing.
Elimination of gRNA plasmid for subsequent rounds of CRMAGE. In order to facilitate sequential 
recombineering cycles, it is beneficial if the plasmid required for the negative selection can be quickly cured, so 
that a new vector can be introduced for the next round of CRMAGE. For this reason we designed the plasmid 
carrying the gRNAs as a self-killing plasmid (pMAZ-SK) by exploiting CRISPR/Cas9 ability to cut the plasmid 
DNA. An L-rhamnose inducible CRISPR natural array encoding two pre-crRNAs that target the origin of the 
plasmid and the kanamycin antibiotic marker was therefore included in the vector. In order to create mature 
active crRNA, the tracrRNA was included on the plasmid under the control of a strong synthetic constitutive 
promoter. This makes it possible to induce plasmid digestion in order to cure the plasmid before starting a new 
round of CRMAGE. We initially determined the minimum amount of time required for successful curing of the 
plasmid by following the number of cells that retained the plasmid after L-rhamnose induction (Fig. 5). After just 
2–3 hours of induction, 92–96% of the cells had lost the plasmid. Interestingly, a complete removal of the plasmid 
was not achieved even after overnight incubation, where 0.2% of the population still retained the plasmid (Fig. 5). 
However, for the practical use for CRMAGE, very efficient plasmid loss can be achieved even after a short incu-
bation time, which will significantly speed up the engineering process. The effective plasmid loss induced by the 
expression of tracRNA and the CRISPR array that targets the plasmid origin and the kanamycin cassette demon-
strates that the processing of the RNA is functional. Using the same principle, it will therefore also be possible to 
include gRNAs that target the pMA7CR_2.0 plasmid, thereby making it possible to remove both plasmids at the 
end of the final engineering cycle.
CRMAGE gRNA design tool. A number of tools are available online for identifying and designing gRNAs 
for various organisms. However, since CRMAGE enables the generation of specific mutations throughout the 
genome, it is necessary to both identify the optimal gRNA for counter selection, as well as the oligos required 
for MAGE. Furthermore, when the specific mutation is not located in close proximity of a PAM sequence, it is 
necessary to identify a nearby PAM sequence that can be included in the MAGE oligo design as described earlier. 
In order to automate the design of both sets of oligos, we have created a web based tool, CRMAGE – Web tool 
(available at http://staff.biosustain.dtu.dk/laeb/crmage/), which guides the user through the necessary steps to 
create a CRMAGE mutated oligos, considering also the option of using degenerate codons if the desired muta-
tion is not located near a PAM sequence. It consists of 3 major steps which include: input of a DNA sequence to 
mutate, user based selection of the base(s) to mutate, and the program finally presents the user with available 
gRNAs near the desired mutation site as well as with options to mutate the PAM site of the gRNA to prevent it 
from selecting against the recombinants. The final output includes the gRNA as well as an SS-DNA oligo to use 
for recombineering that contains both the desired mutation and the one required for negative selection (Fig. 6). 
The highest efficiency will be achieved using an oligo targeting the lagging strand, and the user should account 
for this during the design.
Discussion
CRMAGE is based on the combination of MAGE recombineering with the negative selection against the wild 
type sequence, which can be achieved using CRISPR/Cas9 targeted double strand breaks. In a single round of 
Figure 5. Self-eliminating proprieties of pMAZ-SK plasmid used for negative selection. The graph shows 
the rate of plasmid curing over time. The population was induced with L-rhamnose (to induce self-killing 
crRNA) and aTetracycline (to induce Cas9 expression). Cells were plated on LB plates with and without 
kanamycin. Plasmid loss was calculated as the fraction of kanamycin resistant colonies compared to the total 
number of colonies.
www.nature.com/scientificreports/
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CRMAGE recombineering, we were able to achieve close to 98% efficiency for a single point mutation in galK 
versus 5% using traditional MAGE. The robustness of our system was demonstrated by introducing stop codons 
in two additional targets (lacZ and xylA) with efficiencies between 96.5% and 99.7%. For replacing a larger 6 bp 
RBS sequence, an average of 66% was achieved in two separate types of experiments, while only 6% efficiency was 
reached using traditional MAGE. Such high efficiency with ssDNA oligos and short homology arms (70 bp) has not 
been previously reported. Recently, Pyne at al.20, Jiang et al.21 and Li et al.46, have reported the use of CRISPR-Cas9 
based technology to engineering E. coli with high efficiency. Pyne at al.20 achieved 39% for small insertions (8 bp) 
using dsDNA and 80% for small modifications with ssDNA and Jiang et al.21, could reach efficiencies in the 
range of 72% to 92% relying on long homology arms (300–400 pb), while focusing mainly on large modifications. 
The CRMAGE system additionally enables integration of multiple mutations with no apparent loss of efficiency, 
which is different from previous work where the multiplexing efficiency dropped considerably from 39–47% 
to 0.68-0.25% and from 72–92% to 48–78% in Pyne et al. and Jiang et al. systems respectively20,21. Jiang et al.  
combined gRNA expression cassette and donor DNA into a single vector rather than co-transforming a gRNA 
expressing plasmid and donor DNA. This design requires more laborious cloning steps, especially when targeting 
multiple sites. In the case of CRMAGE, we speculate that the reason for incomplete killing of the WT or rescue of 
the selection plasmid (pMAZ-SK) is the leakiness of the tetracycline and rhamnose promoters that may result in 
a selective pressure during the 5 hours of the whole CRMAGE protocol, which may result in few escapers that will 
not succumb to the negative selection.
It has previously been attempted to modulate chromosomal gene expression in one single step using PCR 
products53. However this work relied on phenotypic screening, and the method leaves FRT scars after the reg-
ulatory element is inserted. The presence of scars in the genome promotes genome rearrangement after several 
Figure 6. CRMAGE Web-Tool. The program guides the user through the necessary steps to create a CRMAGE 
mutated oligos, considering also the option of using a degenerate codon if the desired mutation does not 
contain a PAM itself. It consists of three major steps: (1) Enter (copy/paste) the wild type DNA sequence; (2) 
Select the base to mutate and which base to change to Step 3: Choose the Open Reading Frame and the size of 
the CRMAGE mutation oligo. A list of potential gRNA sites are shown, and the user can pick silent mutations to 
destroy the indicated gRNA PAM site (pointed by the red bracket). Finally the program outputs the CRMAGE 
oligo sequence (shown by the red arrow).
www.nature.com/scientificreports/
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rounds of modifications thus making it difficult to further engineer the strain. With CRMAGE we have demon-
strated that is possible to modulate the protein translation with relatively high efficiency within the population, 
which can be applied to any regulatory element that could be inserted to modulate either the gene expression or 
protein translation.
The CRMAGE system was furthermore designed to enable efficient recycling of the plasmid used for neg-
ative selection by targeting the Cas9 towards the origin and kanamycin cassette in the vector backbone itself. 
Controlled by a L-rhamnose inducible promoter, an almost complete loss (96%) of the plasmid was achieved after 
2–3 hours of induction. This means that it is possible to proceed with subsequent rounds of CRMAGE without 
an intermediate screening for kanamycin sensitive clones. Using the same approach it will also be possible to 
remove the entire CRMAGE system in the last CRMAGE round, where the CRISPR/Cas9 killing activity can 
target origin and antibiotics markers in both plasmids thus resulting in a clean recombinant strain. The idea of 
generating a clean background strain and the possibility to recycle the plasmid containing the gRNA at the end 
of the engineering process has been considered by Jiang et al.21. In their work they have aimed at rescuing the 
plasmid harboring the gRNA for negative selection by induction with IPTG, and the plasmid carrying λ Red and 
Cas9 by growing the culture at 37 °C. However it was not possible to proceed with a subsequent round of recom-
bineering before of 8 or 16 hours of IPTG induction. The use of the temperature sensitive origin used for plasmid 
encoding Cas9 furthermore increases the time required for one single round of recombineering since the growth 
rate of E. coli is significantly reduced at 30 °C. The method presented by Li et al.46 also require significant time per 
engineering cycle. Using CRMAGE it is possible to perform up to two cycles per day since more the 96% curing 
efficiency is reached after only 2–3 h of rhamnose induction, thus making almost unnecessary to plate the cells 
to cure the plasmid.
The timing of expression of the different components of the CRMAGE system has been carefully selected. The 
λ Red system is expressed first, and only after the cells have segregated, the CRISPR system is induced for neg-
ative selection. In a final step, the gRNA expressing plasmid can be cured and a new loop initiated. Constitutive 
expression of the gRNA and Cas9 may cause problems during the replication and the recombineering steps. This 
may explain the higher rate of escapers observed by Li et al.46.
For multiplexing of the CRMAGE targets, it is necessary to express multiple synthetic gRNAs that have signifi-
cant stretches of sequence homology (typically 136 nucleotides). As discussed by Jiang et al., the repeated sgRNAs 
may result in homologous recombination21. Here, we have shown that the presence of a constitutively transcribed 
tracRNA in the pMAZ-SK vector makes it possible to generate multiple gRNAs from a single short region carry-
ing only 30 nucleotides per gRNA followed by a 30 nucleotide repeat between them. The synthesis and cloning of 
such an array of gRNAs (target-repeat-target-repeat etc.) is simple and it minimizes the risk of recombination in 
the vector. The expression of the pre-crRNA for multiplex CRMAGE may substitute the sgRNAs if put under con-
trol of the inducible pLtet promoter, making it easy to control the timing of the expression. The system will most 
optimally use aTetracycline induction for negative selection (when pLtet is used in front of the CRISPR array) and 
L-Rhamnose induction for curing the plasmid.
We furthermore demonstrate that degenerate codon usage can be used to expand the range of CRISPR targets, 
thus creating a powerful tool for targeting virtually any site in the genome and enabling single step engineering 
to create single point mutations as well as larger mutations, as demonstrated by the efficient RBS replacement for 
modulating protein translation. The same design can be applied for creating knock-ins or complete knock-outs, 
depending on the donor oligos. The web based CRMAGE web - tool has been engineered to facilitate the design 
of both the λ Red oligo required for the specific mutation as well as gRNA required for the negative selection 
and together with the convenient USER-cloning-assembly-based system we have developed, speed up the design 
and cloning process. Since CRMAGE enables the generation of multiple mutations in a single cycle and multiple 
cycles within a working day, it has the potential to significantly increase the daily strain engineering capacity. The 
increased efficiency furthermore opens up the possibility of automating genome-scale engineering.
Materials and Methods
Strains, Media and Reagents. E. coli K-12, MG1655 strain with genome integrated repressor from 
pZS4Int-tetR, was used to perform CRMAGE experiments and DH5α strain instead was used for cloning pur-
poses. An MG1655 galK mutant carrying a stop codon in position 38 (TAC > TAG) was constructed using tradi-
tional recombineering with galK 2.2 CRMAGE oligo (Table S1). In an MG1655 strain harboring GFP integrated 
downstream of the glmS gene (the strain was a gift from Dr. S.I. Jensen), the RBS was exchanged with a weak one 
using traditional recombineering with oligo 35 (Table S1) and screened for loss of fluorescence. CRMAGE was 
performed using LB-Lennox (10 g/L tryptone (“Enzymatic digest from caseine”- Fluka Analytical), 5 g/L yeast 
extract (Fluka Analytical), 5 g/L NaCl) supplemented with 0.5 mM of MgSO4 (Sigma). All cultures were grown at 
37 °C, 250 rpm shaking. For cloning Q5 high fidelity Polymerase (NEB), Fasta Digestion enzymes and Buffer from 
Fermantas/Thermo Scientific and USER enzymes from NebLab was used. All oligonucleotides and gblocks were 
synthesized by Integrated DNA Technologies (IDT; Coralville, IA) at the 25 nm scale using standard desalting.
Plasmids constructions and CRMAGE plug and play BioBrick. The pMA7CR_2.0 (AmpR) has been 
constructed by cloning Cas9 and RecX in pMA7 plasmid54,55. RecX was first amplified from purified MG1655 
genome using the primers 1 and 2 (Table S1) and cloned in pZ21MCS50 downstream of pLTet promoter using the 
restriction enzymes KpnI and BamHI. Then the expression cassette, gene + promoter (pLtet_recX), was ampli-
fied and cloned in pMA754,55 with USER using primers 3, 4 and 5, 6 (Table S1) for the pMA7 backbone and 
RecX respectively. Eventually a synthetic operon was created by cloning Cas9 with a strong RBS (AAGGAGA) 
downstream pLTet_recX using primers 7, 8 to amplify the backbone with recX, and 9, 10 to amplify Cas9 directly 
from S. pyogenes M1 genome (ATCC collection) (Table S1). The plasmid pMACR_2.0 comes in combo with 
plasmid pZS4Int-tetR (CAMR)56 that is a single copy plasmid harboring TetR repressor necessary for the control 
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of Cas9 and sgRNA expression. This plasmid can also be integrated in the genome in one single step using the 
helper plasmid pLDR8 [WM2269] (ATCC® 77357) expressing the integrase. The self-killing gRNA plasmid 
(pMAZ-Self-Killing: pMAZ-SK) was designed using pCOLA-duet (Millipore) as backbone vector and it consists 
on two main parts. The first one contains the aTetracycline inducible synthetic gRNA use for negative selection 
and the second one constituted of two subparts for the self-killing (Fig. 1), the pre-crRNA array and the tracr-
RNA. The pre-crRNA array and the tracrRNA were ordered as synthetic oligos and gBlock from Life Technology 
and IDT respectively. The first one, named part1_selfkilling (Table S1) was designed to have the pre-crRNA 
array coding for two crRNA targeting the Origin (Ori) and the antibiotic marker (Kanamycin) of the pCOLA 
backbone, and it was cloned using the restriction enzymes NcoI and PacI after the part containing the tracrRNA 
(part2_selfkilling) was cloned with USER using primers 11 to 14 (Table S1). In the part2_selfkilling compo-
nent, there is the tracrRNA under a constitutive synthetic promoter and a synthetic terminator, both derived 
from igem.part.org (Table S1). Once the two major components of the self-killing plasmid were assembled in the 
pCOLA backbone, the synthetic gRNA for the negative selection was added using primers 17 to 20 (Table S1) 
with USER cloning57. Only the gRNA GFP4 (Table S1) was ordered as a gBlock (from IDT) to have it as a unit 
organized in: the aTetracycline inducible promoter (pLtet), 20 bp target sequence and the general scaffold that 
fuses part of the repeat region of the crRNA and the tracrRNA.
In order to change the target sequence in the synthetic gRNA we have designed a USER-cloning-assembly-based 
plug-and-play system, where it is only necessary to order two oligos to change the synthetic gRNA for the nega-
tive selection. This system relies on USER cloning57: the self-killing backbone was amplified using the universal 
primers 21, 22 (Table S1) containing the uracil, the target sequence can be replaced by changing only 20 internal 
nucleotides of two universal complementary oligo scaffolds (oligo scaffolds 23, 24 shown in Table S1). These oli-
gos were designed to be complementary and when annealed will leave 10 pb overhangs that match the overhangs 
left on the backbone after USER treatment. Therefore it is necessary replace only the 20 bp sequence with the 
new target in a way that the two oligos sequences will be complementary (20 pb sequence on the forward oligo 
has to be complementary to the 20 bp sequence on the reverse oligo). The oligos were ordered without uracil 
making the method very cost efficient, and 10 μ L of each oligo (100 μ M concentrated) was then mixed with 10 μ L 
of Neb Buffer4 and 70 μ L of MilliQ Water (100 μ L reaction in total). The reaction mix was incubated at 95 °C for 
5 minutes and let it cool down slowly overnight. Once the two oligos were annealed, they were mixed with the 
amplified backbone, treated with USER enzymes and directly transformed into chemically competent cells. The 
self-killing plasmid containing the galk2.2 gRNA, xylA and LacZ were obtained with this method using primers 
25–26, 27–28, 29–30 respectively, (Table S1) in just a single day of work. The second gRNA for multiplexing 
was inserted in pMAZ-SK::galK2 using primers 31 to 34 (Table S1). pMA7CR_2.0 and pMAZ-SK sequences are 
shown in Table S1.
CRMAGE protocol. An overnight culture of MG1655::pMA7RCR_2.0 in LB with 100 μ g/mL ampicillin (to 
maintain pMA7CR_2.0), 35 μ g/mL chloramphenicol (to maintain pZS4Int-tetR if not integrated in the genome) 
was shaken at 37 °C. The following day 15 mL of LB with 100 μ g/mL ampicillin, 35 μ g/mL chloramphenicol was 
inoculated with 0.15 mL of the overnight culture in a 250 mL flask (starting OD between 0.02–0.03), incubated at 
37 °C shaking and grown until an OD of 0.5–0.6 (about 1.5–2 hours). λ Red was induced by adding L-arabinose 
to a final concentration of 0.2%, followed by continued shaking at 37 °C for 10–15 minutes. The culture was imme-
diately put in an ice-water bath and left to cool for at least 15–20 minutes. The culture was then pelleted by cen-
trifugation at 6500 x g for 5 minutes at 4 °C, the supernatant was discarded and the pellet resuspended in 35 mL 
of ice-cold MilliQ water. This procedure was repeated two times more, where the pellet was first re-suspended in 
15 mL and then in 1 mL of ice-cold MilliQ water. The 1 mL of cells were finally centrifuged at 6500–7000 x g for 
5 minutes at 4 °C and the supernatant removed completely. Subsequently, cells were prepared for electroporation 
and re-suspended in 400–800 μ L of ice-cold MilliQ water. The MAGE oligonucleotides together with the plasmid 
for negative selection were prepared in advance in an Eppendorf tube containing 0.5 μ L of equimolar amounts of 
each oligo (10 pmol/μ L of each) and 250 ng of the plasmid in MilliQ water. 50 μ L of cells were added to the oligos/
plasmid mix and electroporated at 1.8 kV in a 1 mm gap cuvette, and 950 μ L of LB with 100 μ g/mL ampicillin, 
35 μ g/mL chloramphenicol was added immediately after and the cells were transferred to a new tube (15 mL) and 
left to recover for 1 h at 37 °C with shaking. Kanamycin was added to reach a concentration of 50 μ g/mL and the 
culture was incubated for additional 2 hours.
After 3 hours of incubation, aTetracycline (200 ng/mL) was added and the cells were grown for another 2 hours 
at 37 °C shaking. After this point the cells can either be plated on selective media or the plasmid for the negative 
selection can be rescued to start another round of MAGE. For the plasmid cure, the cells were washed twice with 
fresh LB and resuspended in LB with 100 μ g/mL ampicillin, 35 μ g/mL chloramphenicol, aTetracycline 200 ng/mL 
and 0.2% (w/v) of L-rhamnose. If the cell were left to grow ON, a smaller inoculum (103–104 dilution) was used. If 
the culture was prepared for an immediate subsequent round of CRMAGE, the it was diluted to an OD that allows 
at least 2–3 h of growth before reaching OD:0.5–0.6, which is necessary to start the following round.
CRMAGE Web-Tool. The CRMAGE web-based design tool is available at http://staff.biosustain.dtu.dk/laeb/
crmage/and follows three individual steps as described here: Step 1: Enter the wild type DNA sequence. Simply 
copy/paste or manually enter the sequence. Step 2: Select the base to mutate. Here the user is presented with a 
numbered and spaced version of the sequence entered in step 1 and the user can then click the exact base that 
should be mutated and can select into which base it should be mutated. Step 3: CRMAGE mutation oligo and 
gRNA. In this step the user can select a desired CRMAGE mutation oligo size. The size of the MAGE oligo 
determines which gRNA sites can be used since the program sets that as constraint region from which it samples 
the possible gRNAs to use as “negative selection marker”. The user should then select the correct reading frame. 
Then a list of potential gRNA sites are shown and the user can pick silent mutations with the intent to destroy the 
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indicated gRNA PAM site. Be aware that all silent mutations are shown even if they do not destroy the gRNA PAM 
site. It is up to the user to ensure that the PAM site is destroyed. One or two mutation boxes may be shown next to 
a gRNA target. This is dependent on whether one or two codons cover the PAM site. At the very end of step 3, the 
mutation oligo sequence is presented and can be copy/pasted for synthesis.
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